Blue Jet Healthcare Q1 FY27: PI and API rebound, contrast media timing drag

Blue Jet Healthcare began FY27 with a quarter that showed improving operating momentum, even as year-on-year numbers reflected a softer base in pharma intermediates and APIs. For Q1 FY27, the company reported revenue from operations of INR 293.1 crores, EBITDA of INR 98.1 crores with a 33.5 percent margin, and PAT of INR 78.3 crores with a 26.7 percent margin.

Sequentially, revenue rose 24.9 percent and EBITDA increased 37.6 percent, supported by a higher contribution from the pharma intermediates and API business and operating leverage. Year-on-year, revenue fell 17.4 percent and EBITDA declined 18.9 percent, largely because Q1 FY26 included materially higher pharma intermediates and API sales.

Segment mix: PI and API recovered, contrast media was impacted by timing

In Q1 FY27, pharma intermediates and API revenue rose sharply to INR 121.0 crores (from INR 2.4 crores in Q4 FY26, as per the segment table in the presentation). Management attributed the rebound to a restart in supplies of a specific intermediate after a period of customer destocking in the prior quarters. Management also stated that it has strong order book visibility and expects this performance to be sustainable through FY27.

Contrast media intermediates revenue was INR 115.9 crores in Q1 FY27, down from INR 192.8 crores in Q4 FY26. Management clarified that some customer contracts recognize revenue only upon delivery at the customer location. In Q1, transit delays due to container unavailability and longer transit times led to higher goods-in-transit at quarter end and, therefore, lower recognized sales. Management quantified the goods-in-transit increase at about INR 30 crores versus the opening cut-off, which it indicated would be recognized in the subsequent quarter.

High-intensity sweeteners delivered INR 39.7 crores in Q1 FY27 versus INR 36.8 crores in Q4 FY26. The Others category, including spent oils, industrial mix solvents, and R&D services, contributed INR 15.2 crores.

Margins: operating leverage offset some cost pressure

The quarter showed an improvement in EBITDA margin to 33.5 percent from 30.4 percent in Q4 FY26. Management attributed the expansion to operating leverage on higher sales volumes.

Gross margin was reported at 53 percent on the call, down around three percentage points sequentially. Management noted raw material price increases across the board since March, driven by geopolitical conditions. It also stated that in CDMO style arrangements, customers are generally resilient to pass-through of raw material cost variances, but typically with a lag of a few quarters. No formal price increase clause was triggered in the quarter.

PAT margin was slightly lower sequentially at 26.7 percent versus 27.4 percent in Q4 FY26. Management attributed this to lower other income compared to the prior quarter, which had benefited from higher forex gain.

Strategy and capacity build: Hyderabad R&D, Mahad backward integration, and Vizag platform

A key message from both the presentation and the earnings call was that the quarter’s improvement is being positioned as the early outcome of multi-year investments.

The Hyderabad R&D center is on track and expected to become operational during August 2026, with the first phase of talent already onboarded. Management described this facility as a step-up for process development and CDMO support, and also referenced newer chemistry platforms such as peptides and peptide fragments, GLP-1 intermediates, biocatalysts, continuous manufacturing, and flow synthesis.

At Mahad (Unit 3), the company is executing a backward integration project focused on strategically important contrast media intermediates. Management stated that it has invested about INR 210 crores, with a further INR 40 crores committed in the coming months. It expects commercial contribution during the second half of FY27 and indicated the project is slightly ahead of the previously discussed schedule. Management also noted that once stabilized, the upstream products could have third-party sales potential.

Vizag is being positioned as the company’s next major growth platform. Management stated that it has secured about 100 acres, received consent to establish, and commenced engineering and pre-construction activities. Phase 1 is planned at approximately INR 1,000 crores over the next three years, with FY27 capex expected at around INR 250 crores. Phase 1 includes expanding contrast media capacity, establishing a multipurpose finishing block, creating scale-up capability for a new high-intensity sweetener currently under pilot validation, and building a multipurpose intermediate cluster for rising customer demand.

Capital and sustainability: QIP and ESG credentials

During the quarter, Blue Jet completed a QIP fund raise of INR 800 crores by issuing 1,58,10,276 equity shares at INR 506 per share. Management said this improves financial flexibility and supports execution of the long-term strategy, especially the Vizag and capability expansion.

On sustainability, the company highlighted receipt of an EcoVadis Silver Medal and noted that about 70 percent of energy consumption is sourced through renewable energy, including wind and solar.

Closing perspective

Q1 FY27 combined a recovery in pharma intermediates and APIs with a contrast media quarter affected by logistics-linked revenue timing. The operating margin improvement points to meaningful operating leverage, while management’s commentary also acknowledged raw material price uncertainty and the reality of quarter-end cut-offs.

The next set of milestones is more execution-driven: commissioning the Hyderabad R&D center, progressing Mahad toward H2 FY27 commercial contribution, and moving Vizag Phase 1 from approvals into build-out. With the QIP strengthening the balance sheet and management reiterating visibility in key molecules, the near-term focus shifts to how consistently the company converts pipeline and capacity investments into repeatable growth.